Abeclib 150
Form: Tablet
Strength: 150mg
Generic Name: Abemaciclib
Company: Eskayef Pharmaceuticals Ltd.
MRP:৳ 950.0 (Box=10)
Per Piece: ৳ 95.00
Is Antibiotic: No
Indications
Abeclib 150 is indicated for use with endocrine therapy (such as tamoxifen or an aromatase inhibitor) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence with a Ki-67 score ≥20%. Abeclib 150 is also used in combination with an aromatase inhibitor as initial therapy for postmenopausal women and men with HR-positive, HER2-negative advanced or metastatic breast cancer. Additionally, Abeclib 150 is prescribed alongside fulvestrant for advanced or metastatic breast cancer after disease progression with endocrine therapy or as a monotherapy in advanced or metastatic cases after prior chemotherapy.
Pharmacology
Abeclib 150 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These kinases, when activated by D-cyclins, promote cell cycle progression and proliferation in breast cancer cells. This drug works by inhibiting CDK4/6, blocking Rb phosphorylation, and halting cell cycle progression from G1 to S phase, leading to cell senescence and apoptosis. In preclinical models, its daily administration reduced tumor size either as a standalone treatment or when combined with antiestrogens.
Dosage & Administration
Adults: Abeclib 150 is taken orally, with or without food. The recommended starting dose when used with fulvestrant, tamoxifen, or an aromatase inhibitor is 150 mg twice daily, while as monotherapy, the starting dose is 200 mg twice daily. Dose adjustments may be needed based on individual tolerability and safety.
Interaction
Abeclib 150 should not be used with strong CYP3A inhibitors like ketoconazole. When other moderate CYP3A inhibitors are used, the dosage of this drug should be reduced. Concurrent use of strong or moderate CYP3A inducers should also be avoided to ensure efficacy.
Contraindications
Not applicable.
Side Effects
Common side effects include diarrhea, neutropenia, nausea, abdominal discomfort, infections, fatigue, anemia, leukopenia, reduced appetite, vomiting, headaches, alopecia, and thrombocytopenia.
Pregnancy & Lactation
Abeclib 150 may cause harm to a fetus if administered during pregnancy. Animal studies have shown risks of teratogenicity and reduced fetal weight. Women who are pregnant or may become pregnant should avoid this drug, and effective contraception should be used during treatment and for three weeks after the last dose.
Precautions & Warnings
Monitor for diarrhea and initiate treatment promptly to avoid dehydration or infection. Regular blood counts and liver function tests are recommended. Monitor for interstitial lung disease (ILD), pneumonitis, and signs of venous thromboembolism. If ILD or pneumonitis occurs, discontinue the drug immediately. Be cautious of hepatotoxicity, and adjust treatment accordingly.
Overdose Effects
Not available.
Therapeutic Class
Protein kinase inhibitor.
Storage Conditions
Keep below 30°C, protected from light and moisture. Ensure Abeclib 150 is stored out of the reach of children.